48,453
edits
Difference between revisions of "Libre Pathology talk:Study Group"
Jump to navigation
Jump to search
Libre Pathology talk:Study Group (view source)
Revision as of 08:31, 14 May 2015
, 08:31, 14 May 2015→UNIT 4
(→UNIT 2: subdivide) |
(→UNIT 4) |
||
| Line 101: | Line 101: | ||
{{hidden|What is methylation analysis?|<center>[[Microsatellite instability]]</center>}} | {{hidden|What is methylation analysis?|<center>[[Microsatellite instability]]</center>}} | ||
UNIT 5 | ===UNIT 5=== | ||
{{hidden|What are the four test features required to be documented by the CLIA?|<center>[[Microsatellite instability]]</center>}} | {{hidden|What are the four test features required to be documented by the CLIA?|<center>[[Microsatellite instability]]</center>}} | ||
{{hidden|What are "in vitro diagnostics" vs "laboratory developed tests"?|<center>[[Microsatellite instability]]</center>}} | {{hidden|What are "in vitro diagnostics" vs "laboratory developed tests"?|<center>[[Microsatellite instability]]</center>}} | ||
| Line 108: | Line 108: | ||
{{hidden|What are the six performance characteristics that need to be verified for FDA cleared LDTs or modified FDA cleared/approved tests?|<center>[[Microsatellite instability]]</center>}} | {{hidden|What are the six performance characteristics that need to be verified for FDA cleared LDTs or modified FDA cleared/approved tests?|<center>[[Microsatellite instability]]</center>}} | ||
UNIT 6 | ===UNIT 6=== | ||
{{hidden|List the components of a molecular pathology report.|<center>[[Microsatellite instability]]</center>}} | {{hidden|List the components of a molecular pathology report.|<center>[[Microsatellite instability]]</center>}} | ||
{{hidden|Define analytical sensitivity and clinical sensitivity. |<center>[[Microsatellite instability]]</center>}} | {{hidden|Define analytical sensitivity and clinical sensitivity. |<center>[[Microsatellite instability]]</center>}} | ||